Chooses Automated Pre-Bill Coding Analysis to
Improve Financial Performance
Atlanta, GA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, announced today it has signed a contract with a 350-bed, Cerner-EHR health system based in Missouri. The organization will use eValuator’s automated pre-bill coding analysis technology to help improve revenue integrity and financial performance.
Streamline Health is leading an industry movement to enable every hospital in the country to use pre-bill technology to improve financial performance. With eValuator, providers are identifying and addressing coding issues before they contribute to revenue leakage, denied claims and non-compliance exposure. The company combines this new technology with expert auditing services & support to deliver a complete Revenue Integrity Program to its clients. The eValuator program helps users optimize coding and documentation accuracy for every patient encounter prior to billing, substantially improving current financial performance while also assisting in the transition to new payment models.
“We are pleased to have the opportunity to support this health system with eValuator’s unique pre-bill coding analysis,” said Ben Stilwill, President, Streamline Health. “We look forward to partnering with this client to ensure they are paid accurately for the care they provide.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Media
David Kosloski
Vice President, Marketing & Communications
651.308.1395
david.kosloski@streamlinehealth.net
Investors
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
jacob.goldberger@streamlinehealth.net
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…